Agentic AI in Clinical Trials: Enabling Scalable Solutions
Clinical trials are historically slow and expensive, not because science moves cautiously (though it should), but because operations are fragmented. Data lives in silos, recruitment drags and protocol deviations pile up.
Agentic AI and its ability to perceive context, make bounded decisions and take actions across tool chains can’t speed drug absorption in the body or change a molecule’s mechanisms of action. It can, however, have some serious impact on processes. And in clinical trials, processes determine speed, cost and confidence.
This piece shares a realistic view of where agentic AI is making an impact in clinical trials today, what it will take to scale compliantly and how sponsors can measure progress.
What does “agentic” really mean for trials?
We’re not talking about another chatbot here. Agentic AI, rather, is an orchestration layer that can observe, reason and act:
- Observe signals across all clinical trial data ecosystems: not just electronic health records (EHR), electronic patient-reported outcomes (ePROs), wearable devices and labs – but all operational systems, including Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), Clinical Data Management (CDM), Regulatory Information Management Systems (RIMS) and Real-World Evidence (RWE) platforms. These collectively represent the backbone of modern trials.
- Reason over protocol rules and historical evidence — weighing uncertainty, reconciling conflicting constraints and surfacing traceable rationales.
- Act by driving recruitment, generating lists, drafting protocol amendments, triggering safety events, preparing submission artifacts or integrating risk-based adaptive workflows that can dynamically adjust trial operations based on interim analyses, patient behavior and site performance signals.
The promise isn’t magic; it’s coordination. Done right, these systems reduce handoffs, shorten feedback loops and enable dynamic adaptation to processes that are burdensome to the clinical trial ecosystem.
Where’s the value right now?
Faster & Fairer Recruitment
Recruitment for clinical trials remains the industry’s rate‑limiting step. Agentic systems can surface eligible patients in hours instead of weeks — parsing structured data (International Classification of Diseases (ICD) codes, labs, etc.) and unstructured notes via natural language processing (NLP). But the expert move with agentic AI for patient recruitment is not speed alone; it’s equity and explainability. Well‑designed agents should audit inclusion/exclusion logic to prevent drift and bias and prioritize outreach channels that actually convert (site networks, patient advocacy partners, community clinics, etc.) – all while keeping a transparent trail so investigators can see why a patient was surfaced and why they were excluded.
Preemptive Protocol Design
Most protocol amendments are foreseeable (some are even preventable). Agentic tooling can simulate recruitment and event accrual ahead of time, using historical and real‑world data, inclusion criteria, visit schedules, endpoint definitions, local country law and regulations. Here, there are two practical outputs: feasibility checks that anticipate likely bottlenecks and sensitivity analyses that show the trade‑offs of tightening vs. widening criteria (including diversity impacts).
Continuous Safety & Quality Oversight
The smartest trials don’t just move quickly — they course-correct. Once a study is live, agents act like tireless coordinators: triangulating ePRO signals, wearable vitals, reported adverse events (AEs) and endpoint lab result outliers to surface actionable risks, not noise. Done well, this supports risk‑based monitoring by escalating true safety signals to medical monitors with the supporting evidence pre‑packaged, while maintaining Attributable, Legible, Contemporaneous, Original and Accurate (ALCOA+) data integrity with tamper‑evident logs of every decision the agent made.
Execution of Precision Medicine
Adaptive enrichment isn’t new, but agentic AI sets a higher standard for operational cleanliness. Agents, for example, can support exploratory objectives — helping identify responsive subgroups from biomarker panels and operationalizing cohort splits/dose adjustments within the data to refine primary and secondary endpoints in real time.
Regulatory Readiness on Day One
Submission crunches are an undue reality when standardization and documentation slow operations. Agentic systems can assemble living dossiers — clinical study report (CSR) sections and tables, listings and figures (TLF) — continuously aligned to current industry standards and agency expectations. The goal with AI, of course, is never to auto‑submit. Rather, shorten timelines to make every interim review submission ready.
How does the U.S. Food & Drug Administration (FDA) feel?
As agentic AI accelerates trial operations upstream, the downstream reality is that regulators are adopting the same playbook. The FDA is moving fast to modernize its own use of AI. After a successful pilot in May 2025 that cut some review tasks from days to minutes, the agency ordered a secure, unified GenAI platform across all centers by June 30, 2025 and named a Chief AI Officer to govern it. For sponsors, this means submissions must be cleanly structured, machine-parsable and consistent with emerging FDA guidance on AI-generated and AI-analyzed data. In short: AI-ready documents will move faster through an increasingly AI-enabled FDA. Practically, that means structured authoring, clear data lineage and provenance and including validation artifacts so automated reviewers can trace and trust your claims.
How do we make this real (and trustworthy)?
- Data Foundation: Harmonize core domains (patient, protocol, site, safety) with clear provenance. Synthetic data helps with early testing, but production agents must be trained on high-quality, diverse and governed sources.
- Guardrails: Treat agents like any good practice (GxP) system with model risk management: defined scope, change control, validation and human‑in‑the‑loop checkpoints for high‑impact actions.
- Human Factors: Adoption fails when agents are bolted onto already overloaded workflows. Build narrow, high‑value skills first (screening packet generation, deviation triage, etc.) and integrate at the point of work within a system — CTMS, EDC or safety modules — so teams don’t context‑switch.
- Evidence of Value: Anchor on metrics that matter: time‑to‑first‑patient‑in, screen failure rate, protocol deviation rate, number of amendments, monitoring visit efficiency, time from last‑patient‑last‑visit to database lock, time from lock to filing, etc. If an agent can’t move at least one of these in a controlled pilot, re-evaluate.
What’s a pragmatic path to scale?
When it comes to applying AI agents in clinical operations, the most effective approach is to start small and scale with evidence. Rather than transforming everything at once, sponsors should focus on two clear needle-movers by demonstrating value in what would typically be presumed to be non-critical-path activities, such as the protocol approval process, eligibility screening and outreach orchestration, or deviation triage paired with risk-based monitoring support. By concentrating resources, teams can build early wins that demonstrate value and establish trust.
The rollout should be deliberate: start with a single objective, calculate a baseline and then build the agent behind a human reviewer. Tracking weekly deltas with a “human in the loop” will help improvements be measurable and trustworthy. Along the way, it’s critical to codify guardrails. Documenting decision policies, escalation paths and overrides while keeping logs human-readable is key.
As pilots prove successful, move toward a network of coordinated AI agents. Containerize, version and validate your agents, treating prompts and configurations like code and automating the identification of bias or failure modes. Only when key performance indicators consistently hold across sites and indications should organizations expand into adjacent tasks!
In clinical trials, agentic AI is a disciplined way to connect the people, processes and data you already trust, so that decisions happen faster and with reduced iteration. Sponsors that focus on a few high operationally burdened processes and prove value with guardrails will see timelines compress and confidence rise — leapfrogging competitors without compromising safety.
Learn how EPAM’s industry experts and AI practitioners can support you on your clinical trial modernization journey.
